Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
- Conditions
- Locally Advanced or Unresectable Metastatic Breast CancerStage IV Breast Cancer
- Interventions
- Registration Number
- NCT05840211
- Lead Sponsor
- Gilead Sciences
- Brief Summary
The goal of this clinical study is to see if sacituzumab govitecan-hziy (SG) can improve life spans of people with HR+/HER2- metastatic breast cancer and their tumor does not grow or spread when compared to currently available standard treatments, such as paclitaxel, nab-paclitaxel or capecitabine. The primary objective is to compare the effect of SG relative to the treatment of physician's choice (TPC) on progression-free survival (PFS).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 654
-
Able to understand and give written informed consent.
-
Must have adequate tumor tissue sample preferably from locally recurrent or metastatic site.
-
Documented evidence of HR+ metastatic breast cancer (mBC) confirmed with the most recently available tumor biopsy preferably from a locally recurrent or metastatic site.
-
Documented evidence of HER2- status.
-
Documented PD by computed tomography (CT) or magnetic resonance imaging during or after the most recent therapy per RECIST v1.1 criteria.
-
Candidate for the first chemotherapy in the locally advanced or metastatic setting.
-
Eligible for capecitabine, nab-paclitaxel, or paclitaxel.
-
Individuals must have at least one of the following:
-
Disease progression on at least 2 or more previous lines of endocrine therapy (ET) with or without a targeted therapy in the metastatic setting.
- Disease recurrence while on the first 24 months of starting adjuvant ET will be considered a line of therapy; these individuals will only require 1 line of ET in the metastatic setting.
-
Disease progression within 6 months of starting first-line ET with or without a cyclin-dependent kinase (CDK) 4/6 inhibitor (if ineligible or if unable to access a CDK 4/6 inhibitor) in the metastatic setting.
-
Disease recurrence while on the first 24 months of starting adjuvant ET with CDK 4/6 inhibitor and if the individual is no longer a candidate for additional ET in the metastatic setting.
-
-
Individuals may have received prior targeted therapies, including but not limited to PARP inhibitors (for those with germline BRCA1 or BRCA2 mutations), phosphatidylinositol 3-kinase (PI3K) inhibitors (for those with PIK3CA mutations), or mammalian target of rapamycin (mTOR) inhibitors. However, individuals can no longer be candidates for additional endocrine treatment with or without targeted therapies.
-
Individuals with HIV must be on antiretroviral therapy (ART) and have a well-controlled HIV infection/disease.
-
Demonstrates adequate organ function.
-
Male individuals and female individuals of childbearing potential who engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception.
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Key
-
Progressive disease within 6 months of completing (neo)adjuvant chemotherapy.
-
Locally advanced metastatic breast cancer (mBC) (Stage IIIc) in individuals who are candidates for curative intent therapy at the time of study enrollment.
-
Current enrollment in another clinical study and use of any investigational device or drug (drugs not marketed for any indication) either within 5 half-lives or 28 days prior to randomization, whichever is longer.
- Use of investigational drugs in the category of Selective Estrogen Receptor Degraders are acceptable if last dose was longer than 14 days prior to randomization.
-
Received any prior treatment (including antibody-drug conjugate (ADC)) containing a chemotherapeutic agent targeting topoisomerase I.
-
Received any prior treatment with a trophoblast cell-surface antigen 2 (Trop-2)-directed ADC.
-
Have an active second malignancy.
-
Have an active serious infection requiring antibiotics.
-
Have active hepatitis B virus (HBV) or hepatitis C virus (HCV).
-
Individuals positive for human immunodeficiency virus type 1/2 (HIV-1 or -2) with a history of Kaposi sarcoma and/or Multicentric Castleman Disease.
-
Have a positive serum pregnancy test or are breastfeeding for individuals who are assigned female at birth.
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Treatment of Physician's Choice (TPC) Nab-paclitaxel Participants will receive TPC determined prior to randomization to 1 of the 3 allowed regimens: * paclitaxel 80 mg/m\^2 over 1 hour (± 10 minutes) on Days 1, 8, and 15 of a 28-day cycle. * nab-Paclitaxel 100 mg/m\^2 over 30 minutes (± 10 minutes) on Days 1, 8, and 15 of a 28-day cycle. * capecitabine at 1000-1250 mg/m\^2 twice daily for 2 weeks followed by a 1-week rest period of a 21-day cycle. Sacituzumab Govitecan-hziy (SG) Sacituzumab Govitecan-hziy Participants will receive SG at a dose of 10 mg/kg infusion on Days 1 and 8 of a 21-day cycle. Treatment of Physician's Choice (TPC) Paclitaxel Participants will receive TPC determined prior to randomization to 1 of the 3 allowed regimens: * paclitaxel 80 mg/m\^2 over 1 hour (± 10 minutes) on Days 1, 8, and 15 of a 28-day cycle. * nab-Paclitaxel 100 mg/m\^2 over 30 minutes (± 10 minutes) on Days 1, 8, and 15 of a 28-day cycle. * capecitabine at 1000-1250 mg/m\^2 twice daily for 2 weeks followed by a 1-week rest period of a 21-day cycle. Treatment of Physician's Choice (TPC) Capecitabine Participants will receive TPC determined prior to randomization to 1 of the 3 allowed regimens: * paclitaxel 80 mg/m\^2 over 1 hour (± 10 minutes) on Days 1, 8, and 15 of a 28-day cycle. * nab-Paclitaxel 100 mg/m\^2 over 30 minutes (± 10 minutes) on Days 1, 8, and 15 of a 28-day cycle. * capecitabine at 1000-1250 mg/m\^2 twice daily for 2 weeks followed by a 1-week rest period of a 21-day cycle.
- Primary Outcome Measures
Name Time Method Progression Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Up to approximately 29 months PFS is defined as time from date of randomization until the date of first objective progressive disease (PD) or death from any cause, whichever comes first.
- Secondary Outcome Measures
Name Time Method Duration of Response (DOR) as Assessed by BICR and Investigator per RECIST Version 1.1 Until progression or death, up to approximately 60 months DOR is defined as the time from the first documentation of CR or PR to the earlier of the first documentation of objective PD or death from any cause (whichever comes first).
Percentage of Participants Experiencing Clinically Significant Laboratory and/or Vital Sign Abnormalities First dose date up to 30 days post last dose, up to approximately 60 months Overall Survival (OS) Until death, up to approximately 60 months OS is defined as the time from randomization until the date of death from any cause.
Objective Response Rate (ORR) as Assessed by BICR per RECIST Version 1.1 Until progression, up to approximately 60 months ORR is defined as the proportion of participants who achieve a complete response (CR) or partial response (PR) that is confirmed at least 4 weeks after initial documentation of response.
Time to Deterioration in Version 3.0 EORTC-QLQ-C30 Scores Up to approximately 60 months Time to deterioration from baseline in European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) scores. Scale scores range from 0-100. For functioning and global health status/QoL scales, higher scores indicate better functioning or global health status/QoL. For symptom scales, higher scores indicate greater symptom burden.
Progression Free Survival (PFS) as Assessed by Investigator per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Until progression or death, up to approximately 60 months PFS is defined as time from date of randomization until the date of first objective progressive disease (PD) by investigator assessment according to RECIST v1.1 or death from any cause, whichever comes first.
Change from Baseline in the Physical Functioning Domain Using European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Version 3.0 (EORTC QLQ-C30) at Week 16 Baseline, Week 16 The EORTC QLQ-C30 is composed of global health status/QoL scale; five functional domains (physical, role, emotional, cognitive, and social); three symptom domains (fatigue, nausea and vomiting, and pain); and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties).
The Physical Functioning domain includes 5 questions in which participants will be asked to rate their overall health and overall quality of life as it relates to physical functioning during the past week on a scale from 1 (very poor) to 4 (excellent), with a higher score representing a high QoL.Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) First dose date up to 30 days post last dose, up to approximately 60 months Objective Response Rate (ORR) as Assessed by Investigator per RECIST Version 1.1 Up to approximately 60 months ORR is defined as the proportion of participants who achieve a complete response (CR) or partial response (PR) that is confirmed at least 4 weeks after initial documentation of response.
Trial Locations
- Locations (286)
Samsung Medical Center
🇰🇷Gangnam-Gu, Korea, Republic of
Centro de Atención e Investigación Clínica en Oncología
🇲🇽Yucatán, Mexico
Wojewodzki Szpital Specjalistyczny lm. Stefana Kardynala Wyszynsklego SPZOZ w Lublinie
🇵🇱Lublin, Poland
Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers
🇺🇸Chandler, Arizona, United States
Hospital Alemán
🇦🇷Caba, Argentina
Medizinische Universitat Wien, Univ. Klinik fur Innere Medizin I Klinische Abteilung fur Onkologie
🇦🇹Wien, Austria
Icon Cancer Centre Hobart
🇦🇺Hobart, Tasmania, Australia
Instituto de Investigaciones Clinicas de Mar del Plata
🇦🇷Buenos Aires, Argentina
Instituto de Oncología de Rosario
🇦🇷Rosario, Argentina
University Hospital of Patras
🇬🇷Patras, Greece
Bács-Kiskun Varmegyei Oktatokorhaz, Onkaradiologiai Kozpont
🇭🇺Kecskemét, Hungary
Nagoya University Hospital
🇯🇵Nagoya, Japan
National Cancer Centre Singapore
🇸🇬Singapore, Singapore
Taipei Medical University - Shuang Ho Hospital, Ministry of Health and Welfare
🇨🇳New Taipei City, Taiwan
Chi Mei Hospital, Liouying
🇨🇳Tainan City, Taiwan
Attikon Hospital
🇬🇷Athens, Greece
University Hospital of Heraklion
🇬🇷Heraklion, Greece
Euromedica General Clinic of Thessaloniki
🇬🇷Thessaloniki, Greece
Szabolcs-Szatmar-Bereg Varmegyei Oktatokorhaz, Onkoradiologia
🇭🇺Nyiregyhaza, Hungary
Cancer Institute Hospital of JFCR
🇯🇵Koto-Ku, Japan
Centro Hospitalar Lisboa Norte, EPE
🇵🇹Lisbon, Portugal
National Cancer Center
🇰🇷Goyang-si Gyeonggi-do, Korea, Republic of
Prisma Health - Upstate
🇺🇸Greenville, South Carolina, United States
Austin Health
🇦🇺Melbourne, Victoria, Australia
Astera Cancer Care
🇺🇸East Brunswick, New Jersey, United States
Semmelweis Egyetem, Belgyogyaszati es Onkologiai Klinika
🇭🇺Budapest, Hungary
AZ Klina
🇧🇪Brasschaat, Belgium
University Malaya Medical Centre
🇲🇾Kuala Lumpur, Malaysia
Cliniques Universitaires Saint-Luc
🇧🇪Brussels, Belgium
Centro de Investigacion Clinica Bradford Hill
🇨🇱Recoleta, Chile
Kyoto University Hospital
🇯🇵Kyoto-shi, Japan
Koo Foundation Sun Yat-Sen Cancer Center
🇨🇳Taipei, Taiwan
MD Anderson Cancer Center
🇪🇸Madrid, Spain
Saitama Cancer Center
🇯🇵Kitaadachi-gun, Japan
National Hospital Organization Kyushu Cancer Center
🇯🇵Minami-ku, Japan
Centro Hospitalar de Lisboa Central, E.P.E . - Hospital de Santo Antonio dos Capuchos
🇵🇹Lisbon, Portugal
National Taiwan University Hospital
🇨🇳Taipei, Taiwan
Humber River Hospital
🇨🇦Toronto, Canada
Piedmont Cancer Institute
🇺🇸Atlanta, Georgia, United States
Cleveland Clinic
🇺🇸Cleveland, Ohio, United States
Hospital Britanico de Buenos Aires
🇦🇷Buenos Aires, Argentina
Northwest Georgia Oncology Centers
🇺🇸Marietta, Georgia, United States
CER San Juan Centro Polivalente de Asistencia e Investigación Clínica
🇦🇷San Juan, Argentina
Georgia Cancer Specialist - Annex
🇺🇸Atlanta, Georgia, United States
GenesisCare North Shore (Oncology)
🇦🇺St Leonards, New South Wales, Australia
Hematology Oncology Clinic
🇺🇸Baton Rouge, Louisiana, United States
Penn State Cancer Institute
🇺🇸Hershey, Pennsylvania, United States
Magee-Womens of UPMC
🇺🇸Pittsburgh, Pennsylvania, United States
Stanford Cancer Institute
🇺🇸Palo Alto, California, United States
The University of Kansas Hospital
🇺🇸Kansas City, Kansas, United States
Universitätsklinik für Innere Medizin 3 der PMU
🇦🇹Salzburg, Austria
US Oncology Investigational Products Center (IPC)
🇺🇸Norfolk, Virginia, United States
Florida Cancer Specialist
🇺🇸Saint Petersburg, Florida, United States
David C. Pratt Cancer Center
🇺🇸Saint Louis, Missouri, United States
The Ottawa Hospital Cancer Centre
🇨🇦Ottawa, Canada
Sunshine Hospital (Western Health)
🇦🇺St Albans, Victoria, Australia
Hospital de Clínicas de Porto Alegre - HCPA
🇧🇷Porto Alegre, Brazil
Irmandade da Santa Casa de Misericórdia de Porto Alegre
🇧🇷Porto Alegre, Brazil
Instituto Americas
🇧🇷Rio de Janeiro, Brazil
IMIP - Instituto de Medicina Integral Professor Fernando Figueira
🇧🇷Pernambuco, Brazil
Flinders Medical Centre
🇦🇺Bedford Park, South Australia, Australia
Liverpool Hospital
🇦🇺Liverpool, New South Wales, Australia
HGB - Hospital Giovanni Battista/Mãe de Deus Center
🇧🇷Porto Alegre, Brazil
Hospital São Lucas da PUCRS
🇧🇷Porto Alegre, Brazil
Sun Yat-Sen University Cancer Center
🇨🇳Guangdong, China
The First Affiliated Hospital of Nanchang University
🇨🇳Nanchang, China
The Affiliated Hospital Of Qingdao University
🇨🇳Qingdao, China
BC Cancer-Victoria
🇨🇦Victoria, Canada
Centro del Cancer UC
🇨🇱Region Metropolitana, Chile
The First Hospital of Jilin University
🇨🇳Changchun, China
Clínica de Oncologia de Porto Alegre Ltda - CLINIONCO
🇧🇷Rio Grande Do Sul, Brazil
CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia
🇧🇷Santo Andre, Brazil
Universitaire Ziekenhuis Leuven
🇧🇪Leuven, Belgium
Centro de Oncología de Precisión (COP)
🇨🇱Santiago Region, Chile
Hospital Erasto Gaertner
🇧🇷Paraná, Brazil
Unidade de PesquisasClinicas em Oncologia - UPCO
🇧🇷Rio Grande Do Sul, Brazil
CHU de Québec-Université Laval, Hôpital du Saint-Sacrement
🇨🇦Quebec, Canada
CIONC-Centro Integrado de Oncologia de Curitiba
🇧🇷Paraana, Brazil
West China Hospital Sichuan University
🇨🇳Chengdu, China
James Lind Centro de Investigacion del Cancer
🇨🇱Temuco, Chile
Multiscan s.r.o
🇨🇿Pardubice, Czechia
Chongqing University Cancer Hospital
🇨🇳Chongqing, China
Masaryk Memorial Cancer Institute
🇨🇿Brno, Czechia
Oncocentro APYS
🇨🇱Vina del Mar, Chile
The First Affiliated Hospital of USTC (Anhui Provincial Hospital)
🇨🇳Anhui, China
Centre Georges François Leclerc
🇫🇷Dijon, France
Clinique Francois Chenieux
🇫🇷Limoges, France
Institut Paoli Calmettes
🇫🇷Marseille, France
Hopital Privé des Cotes d'Armor
🇫🇷Plerin, France
Institut Gustave Roussy
🇫🇷Villejuif, France
Institut Curie
🇫🇷Paris, France
Charles General University Hospital, Prague
🇨🇿Prague, Czechia
University Hospital of Larissa
🇬🇷Larissa, Greece
Sir Run Run Shaw Hospital,Zhejiang University School of Medicine
🇨🇳Hangzhou, China
The Second Hospital of Jilin University
🇨🇳Jilin Sheng, China
General Hospital of Ningxia Medical University
🇨🇳Ningxia Hui, China
Universitaetsklinikum Freiburg, Klinik fuer Frauenheilkunde
🇩🇪Baden-Württemberg, Germany
Fakultni Nemocnice Brno
🇨🇿Brno, Czechia
SRH Wald-Klinikum Gera GmbH
🇩🇪Gera, Germany
Alexandra General Hospital
🇬🇷Athens, Greece
Hong Kong Integrated Oncology Centre
🇭🇰Hong Kong, Hong Kong
Queen Mary Hospital
🇭🇰Pok Fu Lam, Hong Kong
CHU Jean Minjoz
🇫🇷Besancon, France
Institut Bergonié
🇫🇷Bordeaux, France
Centre Henri Becquerel
🇫🇷Rouen, France
Institut Universitaire du Cancer de Toulouse Oncopole
🇫🇷Toulouse Cedex 9, France
Universitätsklinikum Mannheim
🇩🇪Mannheim, Germany
Nationales Centrum für Tumorerkrankungen Heidelberg
🇩🇪Heidelberg, Germany
Centro di Riferimento Oncologico - IRCCS
🇮🇹Aviano, Italy
Universitatsklinikum Hamburg-Eppendorf
🇩🇪Hamburg, Germany
Centre Oscar Lambret
🇫🇷Lille, France
Marienhospital Bottrop
🇩🇪Bottrop, Germany
Centre Leon Berard
🇫🇷Lyon, France
University Hospital rechts der Isar Technical University of Munich
🇩🇪Bayern, Germany
HELIOS Klinikum Berlin-Buch
🇩🇪Berlin, Germany
Ico René Gauducheau
🇫🇷Loire Atlantique, France
Centre Hospitalier Lyon-Sud
🇫🇷Pierre-benite, France
Fakultni nemocnice v Motole
🇨🇿Prague 4, Czechia
Krajska nemocnice Tomase Bati Zlin
🇨🇿Zlin, Czechia
Bioclinic of Thessaloniki
🇬🇷Thessaloniki, Greece
Debreceni Egyetem Klinikai Központ
🇭🇺Debrecen, Hungary
Shaare Zedek Medical Center
🇮🇱Jerusalem, Israel
Vivantes Klinikum am Urban
🇩🇪Berlin, Germany
Universitatsklinikum Munster
🇩🇪Munster, Germany
Humanitas Istituto Clinico Catanese
🇮🇹Catania, Italy
Hyogo Medical University Hospital
🇯🇵Nishinomiya-shi, Japan
Okayama University Hospital
🇯🇵Okayama, Japan
Kanagawa Cancer Center
🇯🇵Yokohama, Japan
Center Hospital of the National Center for Global Health and Medicine
🇯🇵Shinjuku-ku, Japan
Gachon University Gil Medical Center
🇰🇷Incheon, Korea, Republic of
Fundacao Champalimaud
🇵🇹Lisbon, Portugal
Hospital General Universitario Gregorio Marañón
🇪🇸Madrid, Spain
Hospital Beata María Ana
🇪🇸Madrid, Spain
Wits Clinical Research
🇿🇦Johannesburg, South Africa
Clinica Integral Internacional de Oncologia S de RL de CV
🇲🇽Puebla, Mexico
Tan Tock Seng Hospital
🇸🇬Singapore, Singapore
The Medical Oncology Centre of Rosebank
🇿🇦Johannesburg, South Africa
Cape Town Oncology Trials
🇿🇦Kraaifontein, South Africa
Wilgers Oncology Centre
🇿🇦Gauteng, South Africa
Nottingham University Hospitals NHS Trust
🇬🇧Nottingham, United Kingdom
Hospital Universitario Reina Sofia
🇪🇸Córdoba, Spain
Kaohsiung Chang Gung Memorial Hospital
🇨🇳Kaohsiung City, Taiwan
Kaohsiung Medical University Chung-Ho Memorial Hospital
🇨🇳Kaohsiung, Taiwan
Xiangya Hospital Central South University
🇨🇳Changsha, China
Guangdong Provincial People's Hospital
🇨🇳Guangzhou, China
The First Affiliated Hospital of Sun Yat-sen University
🇨🇳Guangzhou, China
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
🇨🇳Guangzhou, China
Zhejiang Cancer Hospital
🇨🇳Hangzhou, China
Jiangsu Province Hospital
🇨🇳Jiangsu, China
The First Affiliated Hospital of Soochow University
🇨🇳Jiangsu, China
The Nanchang Third Hospital
🇨🇳Jiangxi, China
Affiliated Cancer Hospital of Shandong First Medical University
🇨🇳Jinan, China
Fudan University Shanghai Cancer Center
🇨🇳Shanghai, China
Tianjin Medical University Cancer Institute & Hospital
🇨🇳Tianjin, China
Hubei Cancer Hospital
🇨🇳Wuhan, China
The Second Affiliated Hospital of Zhejiang University School of Medicine
🇨🇳Zhejiang, China
Henan Cancer Hospital
🇨🇳Zhengzhou, China
Breast Cancer Research Centre - WA
🇦🇺Nedlands, Western Australia, Australia
The Royal Marsden NHS Foundation Trust
🇬🇧London, United Kingdom
Centre Jean Bernard Service d'Oncologie Médicale
🇫🇷Rennes Cedex, France
IRCCS Azienda Ospedaliero-Universitaria di Bologna Policlinico di Sant'Orsola
🇮🇹Bologna, Italy
Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona
🇮🇹Ancona AN, Italy
The First Affiliated Hospital of Xi'an Jiaotong University
🇨🇳Xi'an, China
LMU Klinikum der Universitat München
🇩🇪München, Germany
Universitäts - Frauenklinik
🇩🇪Tübingen, Germany
National Hospital Organization Shikoku Cancer Center
🇯🇵Ehime, Japan
Hospital de Basurto
🇪🇸Bilbo, Spain
Investigational Drug Services, AdventHealth Orlando
🇺🇸Altamonte Springs, Florida, United States
Los Angeles Hematology Oncology Medical Group
🇺🇸Los Angeles, California, United States
University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center
🇺🇸San Francisco, California, United States
Rocky Mountain Cancer Centers, LLP
🇺🇸Littleton, Colorado, United States
Florida Cancer Specialists
🇺🇸Brooksville, Florida, United States
Rutgers Cancer Institute of New Jersey
🇺🇸New Brunswick, New Jersey, United States
Memorial Sloan-Kettering Cancer Center (MSKCC) - New York
🇺🇸New York, New York, United States
Stefanie Spielman Comprehensive Breast Center
🇺🇸Columbus, Ohio, United States
Tennessee Oncology, PLLC
🇺🇸Nashville, Tennessee, United States
MultiCare Regional Cancer Center - Auburn
🇺🇸Auburn, Washington, United States
Vanderbilt University Medical Center - Vanderbilt-Ingram Cancer Center
🇺🇸Nashville, Tennessee, United States
Instituto Alexander Fleming
🇦🇷C.a.b.a., Argentina
Centro Privado de RMI Rio Cuarto S.A.
🇦🇷Cordoba, Argentina
Royal Brisbane and Women's Hospital
🇦🇺Queensland, ME, Australia
St Vincent's Hospital Sydney
🇦🇺Darlinghurst, New South Wales, Australia
Icon Cancer Centre Wesley
🇦🇺Auchenflower, Queensland, Australia
University Hospital Innsbruck
🇦🇹Innsbruck, Austria
Klinikum Wels-Grieskirchen
🇦🇹Wels, Austria
GZA Ziekenhuizen - Campus Sint-Augustinus
🇧🇪Antwerpen, Belgium
CHU UCL Namur-Site STE. Elisabeth
🇧🇪Namur, Belgium
Oncosite - Centro de Pesquisa Clinica e Oncologia
🇧🇷Ijui, Brazil
Hospital Haroldo Juaçaba - Instituto do Câncer do Ceará
🇧🇷Fortaleza, Brazil
Oncoclinicas do Brasil Servicos Medicos AS
🇧🇷Minas Gerais, Brazil
Liga Norte-Rio-Grandense Contra o Câncer
🇧🇷Natal, Brazil
Catarina Pesquisa Clinica
🇧🇷Itajai, Brazil
Hospital Araujo Jorge - Associacao de Combate ao Cancer em Goias
🇧🇷Goiânia, Brazil
Instituto do Câncer - Hospital São Vicente de Paulo
🇧🇷Rio Grande Do Sul, Brazil
Instituto Hemomed Oncologia e Hematologia
🇧🇷São Paulo, Brazil
Clinica de pesquisa e centro de estudos em oncologia ginecológica e mamaria
🇧🇷São Paulo, Brazil
BC Cancer - Kelowna
🇨🇦Kelowna, Canada
Peking University People's Hospital
🇨🇳Beijing, China
Fujian Medical University Union Hospital
🇨🇳Fuzhou, China
Harbin Medical University Cancer Hospital
🇨🇳Heilongjiang, China
University Hospital Olomouc
🇨🇿Olomouc, Czechia
Institut Regional du Cancer de Montpellier
🇫🇷Montpellier Cedex 5, France
Universitätsklinik Erlangen
🇩🇪Erlangen, Germany
Medizinische Hochschule Hannover
🇩🇪Hannover, Germany
Prince of Wales Hospital
🇭🇰New Territories, Hong Kong
Oncology Institute Rambam Health Care Campus
🇮🇱Haifa, Israel
Rabin Medical Center
🇮🇱Petah Tikva, Israel
Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont
🇭🇺Szeged, Hungary
Hadassah Medical Center
🇮🇱Jerusalem, Israel
Tel Aviv Sourasky Medical Center
🇮🇱Tel Aviv, Israel
Sheba Medical Center
🇮🇱Ramat Gan, Israel
Humanitas Gavazzeni
🇮🇹Bergamo, Italy
ASST Papa Giovanni XXIII
🇮🇹Bergamo, Italy
Azienda Ospedaliera Mater Domini
🇮🇹Catanzaro, Italy
IRCCS Ospedale Policlinico San Martino
🇮🇹Genova GE, Italy
Fondazione IRCCS San Raffaele del Monte Tabor
🇮🇹Milano, Italy
Azienda Ospedaliera San Gerardo
🇮🇹Monza, Italy
Istituto Nazionale Tumori IRCCS Fondazione G. Pascale
🇮🇹Napoli, Italy
Istituto Europeo di Oncologia
🇮🇹Milan, Italy
Istituto Oncologico Veneto IOV
🇮🇹Padova, Italy
Irccs Crob
🇮🇹Rionero in Vulture, Italy
Azienda Ospedaliero-Universitaria Policlinico Umberto I
🇮🇹Roma, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
🇮🇹Roma, Italy
Tohoku University Hospital
🇯🇵Aoba-ku, Japan
Istituto Clinico Humanitas
🇮🇹Rozzano, Italy
Aichi Cancer Center Hospital
🇯🇵Aichi, Japan
Juntendo University Hospital
🇯🇵Bunkyo-ku, Japan
Chiba Cancer Center
🇯🇵Chiba, Japan
National Cancer Center Hospital
🇯🇵Chuo-ku, Japan
Osaka Prefectural Hospital Organization Osaka International Cancer Institute
🇯🇵Chuo-ku, Japan
Fukushima Medical University Hospital
🇯🇵Fukushima, Japan
Social Medical Corporation Hakuaikai Sagara Hospital
🇯🇵Kagoshima-shi, Japan
Tokai University Hospital
🇯🇵Kanagawa, Japan
National Cancer Center Hospital East
🇯🇵Kashiwa, Japan
Kumamoto University Hospital
🇯🇵Kumamoto- shi, Japan
Hiroshima City Hiroshima Citizens Hospital
🇯🇵Naka-ku, Japan
Gunma Prefectural Cancer Center
🇯🇵Ota, Japan
National Hospital Organization Hokkaido Cancer Center
🇯🇵Sapporo, Japan
Showa University Hospital
🇯🇵Tokyo, Japan
Kyungpook National University Chilgok Hospital
🇰🇷Gyeongsangbuk-do, Korea, Republic of
Seoul National University Bundang Hospital
🇰🇷Seongnam, Korea, Republic of
Korea University Anam Hospital
🇰🇷Seoul, Korea, Republic of
Severance Hospital, Yonsei University Health System
🇰🇷Seoul, Korea, Republic of
Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of
Hospital Kuala Lumpur
🇲🇾Kuala Lumpur, Malaysia
Sarawak General Hospital
🇲🇾Kuching, Malaysia
Institut Kanser Negara
🇲🇾Putrajaya, Malaysia
COI Centro Oncologico Internacional S.A.P.I. de C.V.
🇲🇽Mexico City, Mexico
Hospital Universitario Dr. José Eleuterio González
🇲🇽Monterrey, Mexico
Centro de Investigacion y Avances Medicos Especializados
🇲🇽Cancún, Mexico
FUCAM
🇲🇽México, Mexico
Centro Medico Zambrano Hellion
🇲🇽San Pedro Garza García, Mexico
Copemicus Podmiot Leczniczy Wojewodzkie Centrum Okologii w Gdansku
🇵🇱Gdansk, Poland
Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie Sp. z.o.o
🇵🇱Krakow, Poland
Instytut MSF Sp. z o.o.
🇵🇱Lodz, Poland
Maria Sklodowska - Curie Institute of Oncology
🇵🇱Warszawa, Poland
LUX MED Onkologia Sp. Zo.o.
🇵🇱Warszawa, Poland
Centro Clinico Academico - Hospital de Braga
🇵🇹Braga, Portugal
Hospital da Senhora da Oliveira Guimaraes
🇵🇹Guimarães, Portugal
Unidade Local de Saude de Matosinhos EPE - Hospital Pedro Hispano
🇵🇹Matosinhos, Portugal
National University Hospital
🇸🇬Singapore, Singapore
Hospital Clinic de Barcelona
🇪🇸Barcelona, Spain
Hospital Universitari Dexeus
🇪🇸Barcelona, Spain
Hospital Universitari Vall D'Hebron
🇪🇸Barcelona, Spain
Hospital General Universitario De Elche
🇪🇸Elche, Spain
Hospital Universitario de Jaen
🇪🇸Jaen, Spain
Hospital Universitario Ramón y Cajal
🇪🇸Madrid, Spain
Hospital Clinico San Carlos
🇪🇸Madrid, Spain
Hospital Universitario de Salamanca
🇪🇸Salamanca, Spain
Hospital Universitario 12 de Octubre
🇪🇸Madrid, Spain
Hospital Universitario Virgen Macarena
🇪🇸Sevilla, Spain
Hospital Clínico Universitario de Santiago de Compostela - CHUS
🇪🇸Santiago de Compostela, Spain
Hospital Universitario Virgen del Rocio
🇪🇸Seville, Spain
Instituto Valenciano De Oncologia (IVO)
🇪🇸Valencia, Spain
Hospital Clínico Universitario de Valencia
🇪🇸Valencia, Spain
National Cheng Kung University Hospital
🇨🇳Tainan, Taiwan
Taipei Veterans General Hospital
🇨🇳Taipei City, Taiwan
Tri-Service General Hospital
🇨🇳Taipei, Taiwan
Barts Cancer Institute
🇬🇧London, United Kingdom
Chang Gung Memorial Hospital, Linkou
🇨🇳Taoyuan City, Taiwan
University College London Hospitals
🇬🇧London, United Kingdom
The Christie NHS Foundation Trust
🇬🇧Manchester, United Kingdom
Asan Medical Center
🇰🇷Seoul, Korea, Republic of
Yale-New Haven Hospital-Yale Cancer Center
🇺🇸New Haven, Connecticut, United States
Saint Luke's Cancer Institute
🇺🇸Kansas City, Missouri, United States
Fujian Cancer Hospital
🇨🇳Fujian, China